Emcure: Stock jumps after launching semaglutide injection Poviztra for weight management
News by Aliceblue News Desk
22 Dec 2025
Introduction
Leading pharmaceutical company launched Poviztra®, a semaglutide injection for weight management in India, available in five strengths with once-weekly pen device, priced from ₹8,790 per month for chronic obesity care.
Also Read: GPT Infraprojects shares gain with new construction project worth ₹1804.48 Cr, catch details
Share price movement of Emcure Pharmaceuticals
On December 22, 2025, Emcure Pharmaceuticals Ltd opened at ₹1,387.05, up 0.13% from its previous close of ₹1,385.40. The stock reached a high of ₹1,398.10 (+0.93%) and a low of ₹1,375.35 (-0.73%). By 3:16 PM, it traded at ₹1,376.80, a -0.62% decrease, with a market cap of ₹26,099.29 crore.
Emcure Launches Poviztra® for Weight Management
Emcure Pharmaceuticals Ltd. launched Poviztra®, a semaglutide injection for weight management, across India. The product is available in a once-weekly pen device in five strengths with starting price ₹8,790 per month.
Poviztra® supports chronic weight management in adults with BMI ≥30 kg/m² or ≥27 kg/m² with comorbid conditions. It is also indicated to reduce cardiovascular risks in high-risk adults.
The semaglutide injection is backed by STEP and SELECT clinical trials and nearly a decade of global use, demonstrating strong safety, efficacy, and real-world effectiveness for weight reduction and health outcomes.
Stock performance of Emcure Pharmaceuticals for Period of 1 week, 6 months, and 1 year
Emcure Pharmaceuticals Ltd delivered a -0.75% return over the past week, gained 3.71% over the past six months, and increased 0.88% over the past year.
Also Read: Seamec awards USD 3.25 Mn diving services contract to Adsun Offshore
Shareholding pattern of Emcure Pharmaceuticals
| Particulars | Sep 2025 | Jun 2025 | Mar 2025 |
| Promoter | 77.90% | 77.90% | 77.90% |
| FII | 3.30% | 2.90% | 3.10% |
| DII | 4.40% | 2.80% | 3.40% |
| Public | 14.50% | 16.40% | 15.60% |
About Emcure Pharmaceuticals
Emcure Pharmaceuticals Ltd (NSE: EMCURE), established in 1981 and headquartered in Pune, develops, manufactures, and markets a wide range of pharmaceutical products globally, ranking 13th in India for domestic sales as of October 2025.
Stay Ahead with the Latest Stock Market Updates – Click Here
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.
FAQs
Q: Why is Emcure Pharmaceuticals share price going up today?
A: Emcure Pharmaceuticals share price is rising after launching Poviztra®, a semaglutide injection for weight management in India.
Q: What does Emcure Pharmaceuticals Ltd specialize in?
A: Emcure Pharmaceuticals Ltd specializes in developing, manufacturing, and globally marketing a broad range of pharmaceutical products across multiple therapeutic areas.
Q: What is the market capitalization of Emcure Pharmaceuticals Ltd?
A: Emcure Pharmaceuticals Ltd has a market capitalization of ₹26,099.29 crore as of December 22, 2025.
News Author
Aliceblue News Desk
